Preclinical development of a miR-132 inhibitor for heart failure treatment

miR-132 was shown to drive pathological cardiac remodeling, a hallmark of heart failure. Here, the authors show that an antisense inhibitor of miR-132 has favourable pharmacokinetics, safety-tolerability and preclinical efficacy in mouse and porcine models of heart failure.

Uloženo v:

Podrobná bibliografie
Hlavní autoři:	Ariana Foinquinos, Sandor Batkai, Celina Genschel, Janika Viereck, Steffen Rump, Mariann Gyöngyösi, Denise Traxler, Martin Riesenhuber, Andreas Spannbauer, Dominika Lukovic, Natalie Weber, Katrin Zlabinger, Ena Hašimbegović, Johannes Winkler, Jan Fiedler, Seema Dangwal, Martin Fischer, Jeanne de la Roche, Daniel Wojciechowski, Theresia Kraft, Rita Garamvölgyi, Sonja Neitzel, Shambhabi Chatterjee, Xiaoke Yin, Christian Bär, Manuel Mayr, Ke Xiao, Thomas Thum
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Nature Portfolio 2020-01-01
Edice:	Nature Communications
On-line přístup:	https://doi.org/10.1038/s41467-020-14349-2
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Preclinical development of a miR-132 inhibitor for heart failure treatment

Podobné jednotky